new
   Indications of Cemiplimab
503
Sep 18, 2025

Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody that activates the immune system to fight against tumors by inhibiting the PD-1/PD-L1 pathway.

Indications of Cemiplimab

Core Indications

It is indicated for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), specifically including:

Metastatic CSCC (lymph node or distant metastasis)

Locally advanced CSCC (cannot be cured by radical surgery or radiotherapy)

Application Conditions

Patients with active autoimmune diseases, a history of organ transplantation, or previous treatment with PD-1/PD-L1 inhibitors must be excluded.

Treatment should be continued until disease progression or the occurrence of intolerable toxicity.

Specifications and Properties of Cemiplimab

Dosage Form and Specifications

Injection: 350mg/7mL (50mg/mL), supplied in single-dose vials.

Properties

Cemiplimab Injection is a clear to slightly opalescent, colorless to pale yellow solution, which may contain trace amounts of translucent to white particles.

The pH value of the solution is 6, and the main active ingredient is cemiplimab-rwlc with a molecular weight of approximately 146 kDa.

Physicochemical Characteristics

pH Value: 6.0 (L-histidine buffer system)

Excipients: Contains sucrose (50mg/mL), L-proline, polysorbate 80 (2mg/mL), and no preservatives.

Precautions

A visual inspection is required before use. If the solution is turbid, discolored, or contains foreign particles other than trace translucent to white particles, the vial should be discarded.

A special reminder: This drug must not be shaken, so as to avoid affecting its efficacy.

Storage Methods of Cemiplimab

Storage of Unopened Products

Temperature: 2°C–8°C (refrigerated storage), protected from light in the original packaging.

Prohibited Operations: Freezing, shaking, or direct exposure to light.

Storage After Preparation

Diluent: Must be diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a concentration of 1–20mg/mL.

Time Limit: At room temperature (≤25°C): Infusion must be completed within 8 hours.

Refrigerated Storage (2°C–8°C): Infusion must be completed within 24 hours.

Other Requirements: The diluted solution must be brought to room temperature before infusion, and re-freezing is prohibited.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Cemiplimab(Libtayo)
PD-1 inhibitor for advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer under specific conditions.
RELATED ARTICLES
Precautions for Cemiplimab Administration

Cemiplimab is a PD-1 inhibitor indicated for the treatment of metastatic or locally advanced cutaneous squamous cell...

Thursday, September 18th, 2025, 16:10
How to Use Cemiplimab

Cemiplimab is a monoclonal antibody targeting PD-1, indicated for the treatment of metastatic or locally advanced...

Thursday, September 18th, 2025, 16:04
Indications of Cemiplimab

Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody that activates the immune system to fight...

Thursday, September 18th, 2025, 15:59
Indications for Cemiplimab

Cemiplimab is an immune checkpoint inhibitor primarily used for treating specific types of skin cancer. It activates...

Thursday, September 4th, 2025, 15:07
RELATED MEDICATIONS
Crizotinib
Certain ALK- or ROS1-positive cancers in adults and children.
TOP
1
Dacomitinib
​A kinase inhibitor indicated for the first-line treatment of metastatic...
TOP
2
Cemiplimab
PD-1 inhibitor for advanced cutaneous squamous cell carcinoma, basal cell...
TOP
3
Adagrasib
Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have...
Selpercatinib
Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC)...
Mobocertinib
Adult patients with locally advanced or metastatic non-small cell lung cancer...
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved